Synergy Pharmaceuticals Inc

Synergy Pharmaceuticals — Technical Presentation (October 2010)

20 slides from Synergy Pharmaceuticals's technical presentation, Oct 18, 2010

  1. Slide 1: Phase IIa Study of Plecanatide (SP-304) in Chronic Idiopathic Constipation

    A Phase IIa Randomized, Double-Blind, Placebo-Controlled, 14-Day Repeat, Oral, Dose-Ranging Study to Assess the Safety, Pharmacokinetic and Pharmacodynamic Effects of Plecanatide (SP-304) in Patients with Chronic Idiopathic Constipation (Protocol No. SP-SP304201-09) K. Shailubhai, C. Talluto,S. Comi

  2. Slide 2: Background

    Background Uroguanylin (UG) and guanylin (GN) are physiological agonists of guanylate cyclase-C (GC-C) receptor. Activation of the GC-C receptor stimulates intracellular synthesis of cyclic GMP, resulting in activation of the cystic fibrosis transmembrane conductance regulator (CFTR). Activation of

  3. Slide 3: Known mammalian agonists of GC-C

    Fig. 1: Known mammalian agonists GC-C N S S N Y C C E L C C N P A C T G C Y E. Coli ST Q E E C E L C I N M A C T G Y Lymphoguanylin Guanylin S H T C E I C A F A A C A G C N D D C E L C V N V A C T G C L Uroguanylin A B Uroguanylin and E. coli enterotoxin ST peptide bind to the same GC-C receptors an

  4. Slide 4: GC-C signaling in the intestine

    Cross section of intestine GC-C signaling in the intestine Binding of GC-C agonists to their receptors located in the GI lumen stimulates fluid, chloride and bicarbonate secretions. Optimal volume of fluid secretion in the proximal intestine is essential for normal bowel movement. Reduced volume of

  5. Slide 5: Plecanatide is a superior analog of the natural GI hormone uroguanylin

    Uroguanylin Plecanatide Fig.3: Plecanatide is a superior analog of the natural GI hormone uroguanylin N D D C E L C V N V A C T G C L N D E C E L C V N V A C T G C L

  6. Slide 6: Objectives

    Objectives Primary Objective: To evaluate the safety of plecanatide for 14 days in patients with CC Secondary Objectives: To assess the pharmacokinetic profile after the first daily dose of plecanatide and prior to and after the last dose of plecanatide To assess the time to first bowel movement aft

  7. Slide 7: Methods

    Methods This was a Phase IIa, randomized, double-blind, placebo-controlled, 14-day repeat, oral, dose-ranging study There were four dose cohorts in this trial: Plecanatide (0.3 mg, 1.0 mg, 3.0 mg or 9.0 mg) and matching placebo. 3:1 randomization (plecanatide:matching placebo) 20 subjects per dose c

  8. Slide 8: Primary Subject Selection Criteria

    Primary Subject Selection Criteria: Meet modified ROME III criteria for CC Colonoscopy within past 5 years with no significant finding Good health as determined by physical examination, medical history, vital signs, ECG, clinical chemistry, hematology, urinalysis, drug screen and serology assessment

  9. Slide 9: Statistical Analysis

    Statistical Analysis Primary endpoints for the safety evaluation were summarized by descriptive statistics for the patients that received at least one dose of plecanatide or placebo (safety population) The secondary assessments for pharmacodynamic activity were summarized by descriptive statistics f

  10. Slide 10: Results - Demographics

    Results - Demographics Placebo 0.3 mg 1.0 mg 3.0 mg 9.0 mg Age * 47.7 (14.6) 51.1 (11.9) 50.5 (10.6) 48.5 (16.1) 47.3 (12.7) Gender Female 18 (90%) 12 (85.7%) 14 (100%) 13 (86.7%) 12 (80%) Male 2 (10%) 2 (14.3%) 0 (0%) 2 (13.3%) 3 (20%) Race Caucasian 17 (85%) 13 (92.9%) 12 (85.7%) 14 (93.3%) 12 (80

  11. Slide 11: Results - Safety

    No detectable systemic absorption of plecanatide (assay sensitivity > 10 ng/mL) No serious adverse events (SAE) reported in subjects receiving plecanatide No deaths reported in this study % subjects who reported AEs considered related to treatment Placebo 10% (2/20) Plecanatide 17.2% (10/58) % subje

  12. Slide 12: GI-Related Adverse Event Summary with Relationship to Treatment

    Table 2: GI-Related Adverse Event Summary with Relationship to Treatment AE Placebo n=20 0.3 mg n=14 1.0 mg n=14 3.0 mg n=15 9.0 mg n=15 Ab Cramping 1 (5.0%) 0 0 0 0 Ab Pain 1 (5.0%) 0 0 0 0 Bloating 0 0 0 0 1 (6.7%) Diarrhea 1 (5.0%) 0 0 0 0 Flatulence 2 (10.0%) 0 0 0 0 Nausea 0 1 (7.1%) 0 0 1 (6.7

  13. Slide 13: Results - Efficacy: Plecanatide reduces the time to first bowel movement

    Figure 4: Plecanatide reduces the time to first bowel movement Median reduction in time to first BM (hours) n= 16 n= 12 n=14 n= 13 n=15 n=54 Results - Efficacy Median time to first BM (hours) 0 5 10 15 20 25 placebo 0.3 mg 1.0 mg 3.0 mg 9.0 mg all

  14. Slide 14: Change from Baseline in Complete Spontaneous Bowel Movements

    Figure 6: Change from Baseline in Complete Spontaneous Bowel Movements (CSBM) after 14-Days of Treatment (Per Protocol Population) 0.0 1.0 2.0 3.0 4.0 5.0 Placebo 0.3mg 1.0mg 3.0mg 9.0mg Overall Tx Plecanatide Dose (mg) Average Number of CSBM/wk Pre-Treatment 14-Day Treatment

  15. Slide 15: Change from Baseline in Bristol Stool Form Score

    Figure 7: Change from Baseline in Bristol Stool Form Score (BSFS) after 14-Days of Treatment (Per Protocol Population) 0.0 1.0 2.0 3.0 4.0 5.0 Placebo 0.3mg 1.0mg 3.0mg 9.0mg Overall Tx Plecanatide Dose (mg) Average Weekly BSFS Pre-Treatment 14-Day Treatment

  16. Slide 16: Change from Baseline in Straining Scores

    Figure 8: Change from Baseline in Straining Scores after 14-Days of Treatment (Per Protocol Population) 0.0 1.0 2.0 3.0 4.0 5.0 Placebo 0.3 mg 1.0 mg 3.0 mg 9.0 mg Overall Tx Plecanatide Dose (mg) Average Weekly Straining Score Pre-Treatment 14-Day Treatment

  17. Slide 17: Improvements in Abdominal Discomfort Scores

    Figure 9: Percent of Subjects Reporting Improvements in Abdominal Discomfort Scores after 14-Days of Treatment (Per Protocol Population) 0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 Placebo 0.3 mg 1.0 mg 3.0 mg 9.0 mg Overall Tx Treatment Groups % of Subjects Reporting Improvement in Abdominal Discom

  18. Slide 18: Patient Global Assessment Questionnaire: Constipation Severity

    Patient Global Assessment Questionnaire Constipation Severity 0 20 40 60 80 Placebo 0.3 1.0 3.0 9.0 Overall Tx Plecanatide Dose (mg) % of Subjects Reporting Improvement in Constipation Severity Pre-Treatment 14-Day Treatment

  19. Slide 19: Patient Global Assessment Questionnaire: Overall Relief

    Patient Global Assessment Questionnaire Overall Relief % of Subjects Reporting Overall Relief 0 20 40 60 80 100 Pre-Treatment 14-Day Treatment Placebo 0.3 1.0 3.0 9.0 Overall Tx Plecanatide Dose (mg)

  20. Slide 20: Conclusions

    Conclusions There was no detectable systemic absorption of plecanatide at any dose up to 9 mg (assay sensitivity: 10 ng/mL) The safety profile demonstrated minimal adverse events No SAEs reported in subjects receiving plecanatide No reports of diarrhea in subjects who received plecanatide All plecan

Synergy Pharmaceuticals — Technical Presentation (October 2010) on 6ix